Exact Sciences biotech accolade leaves Abbott stock consolidating amid bearish momentum and oversold signals

Exact Sciences biotech accolade leaves Abbott stock consolidating amid bearish momentum and oversold signals
Abbott slides 0.82% today

Abbott congratulated its new cancer diagnostics colleagues from Exact Sciences for being recognized on the Fast Company Most Innovative Companies biotech list.

Abbott stated that advancing cancer care includes transforming possibilities for testing. Details are being clarified.

Highlights

  • Abbott trades in a firmly bearish trend, consistently below key moving averages and facing sustained selling pressure across timeframes.
  • Short-term indicators flag oversold conditions and weak trend momentum, raising the potential for a brief technical rebound.
  • Expected range for the coming week is $100.50–$105.50, with a high probability of further downside if support at $102.41 fails.

Abbott (ABT) is trading at $103.11, positioned well below the MA-20 ($108.77), MA-50 ($111.04), and MA-200 ($124.95), indicating persistent selling pressure across short, medium, and long-term trends. The Ichimoku Kijun on D1 sits at $109.60, placing immediate resistance above the current price. Near-term support is found at the MA-5/MA-10 cluster around $104.45–$106.42, while further downside is buffered by the 52-week low ($102.41). Immediate resistance aligns at the Ichimoku Kijun ($109.60), with key resistance at the MA-50 ($111.04).

Momentum readings on D1 remain firmly bearish, with MACD showing a strong sell signal and ADX indicating trend weakness. RSI (32.56), Stoch RSI (8.42), and CCI (–119.60) all point toward oversold conditions, suggesting the asset is under heavy pressure but may be due for a technical bounce. BBP registers at –1.39, confirming sellers dominate intraday momentum, while the AO offers further downside confirmation. Over the past week, Abbott has fallen $0.85 (0.89%) from the previous close of $103.96, now trading at the very bottom of the weekly range, with weekly volatility standing at 3.49%. This marks a steady decline from the weekly high (105.98) and hints at sustained bearish sentiment.

For the upcoming week, the expected trading range is $100.50 to $105.50, staying just above the 52-week low and well below the annual high of $139.06. There is a very high probability (more than 80%) of further downside, with the risk of recovery seen as limited based on strictly bearish signals from all D1 and W1 trend indicators, including MACD, RSI, and moving averages. The baseline scenario suggests Abbott will consolidate within this range, with limited upside attempts. A bullish scenario would require a sustained breakout above $105.50, targeting resistance at $109.60, but this appears unlikely given the current technicals. If ABT breaks below $102.41–$100.50, a new yearly low is likely, reinforcing the bearish case in the short term.

Previously it was reported that analysts saw persistent downside pressure on Abbott's shares, with technical indicators suggesting a continued bearish outlook. Building on that assessment, investors should remain attentive to any shift in volume or news flow, as these could signal a potential change in momentum and present new trading opportunities.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.